Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M57.7Revenue $M0.0Net Margin (%)--Altman Z-Score--
Enterprise Value $M57.7EPS $-0.8Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M28.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IMCL

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

IMCL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


IMCL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ICAHN CARL CDirector, 10% Owner 2008-11-21Sell11,669,544$70-93.57 view
CROWLEY RichardSVP, Biopharmaceutical Ops 2008-11-03Sell11,957$68.72-93.45 view
CROWLEY RichardSVP, Biopharmaceutical Ops 2008-09-02Sell11,957$64.4-93.01 view
CROWLEY RichardSVP, Biopharmaceutical Ops 2007-11-19Sell9,150$42.65-89.45 view
BAILEY MICHAEL PSVP, Commercial Ops 2007-11-19Sell14,750$64.16-92.99 view
CROWLEY RichardSVP, Biopharmaceutical Ops 2007-11-19Sell26,957$64.16-92.99 view
Johnson John HCEO 2007-09-07Buy13,609$36.74-87.75 view
BAILEY MICHAEL PSVP, Commercial Ops 2007-07-12Sell1,250$34.2-86.84 view
RAMANATHAN ERIKSenior Vice President, Legal 2006-10-13Sell9,996$30.9-85.44 view
RAMANATHAN ERIKSenior Vice President, Legal 2006-10-10Sell5,004$30.92-85.45 view

Press Releases about IMCL :

Quarterly/Annual Reports about IMCL:

    News about IMCL:

    Articles On GuruFocus.com
    Spotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous Croto Aug 24 2015 

    More From Other Websites
    IMMUNOCLIN CORP Financials Aug 29 2015
    Spotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous... Aug 24 2015
    IMMUNOCLIN CORP Financials Jul 22 2015
    Linking cancer drug prices to their performance May 27 2015
    ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part... May 20 2015
    Subsidiary of ImmunoClin Corporation (IMCL) receives controlled drug license in the United Kingdom Apr 02 2015
    Activist investor at Ariad Pharmaceuticals has long history of wins Mar 11 2015
    ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK Mar 10 2015
    Activists want 'imminent retirement' of Ariad CEO Feb 20 2015
    IMMUNOCLIN CORP Files SEC form 10-Q, Quarterly Report Dec 22 2014
    Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr.... Nov 06 2014
    IMMUNOCLIN CORP Files SEC form 10-Q, Quarterly Report Sep 29 2014
    Cannabis Science, Inc. (CBIS) Signs Drug Development and Laboratory Services Agreement with... Sep 29 2014
    IMMUNOCLIN CORP Files SEC form 8-K, Other Events Aug 01 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK